A comparison of oncology and non-oncology appraisals

ISPOR 2019 Are patient access schemes and commercial access schemes essential for NICE to recommend access? A comparison of oncology and non-oncology appraisals


In England, the National Institute of Health and Care Excellence (NICE) uses the cost of treatment per quality-adjusted life-year as the basis for its’ decision making. In general, technologies will only receive a positive NICE recommendation if their estimated cost per QALY is below the 20 000 to 30 000 incremental cost-effectiveness ratio threshold. In order to demonstrate cost-effectiveness, manufacturers must often agree financial agreements (such as confidential discounts) with NHS England. In this study, we compared the use of financial agreements for oncology and non-oncology drugs assessed by NICE between 2017 and 2019

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.